Safusidenib is under clinical development by AnHeart Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Safusidenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Safusidenib overview
DS-1001 is under development for the treatment of IDH1 mutated solid tumor, malignant glioma, low grade glioma, acute myelocytic leukemia (AML) and cholangiocarcinoma. It is administered orally formulated as capsule. The drug candidate targets IDH1 mutant cancer cells. It was also under development for chondrosarcoma.
AnHeart Therapeutics overview
AnHeart Therapeutics, a subsidiary of AnHeart Therapeutics Hangzhou Co Ltd, is a clinical stage biopharmaceutical company that focuses on oncology drugs to address unmet medical needs and underserved markets. AnHeart Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of Safusidenib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
